Form 4: aTyr Pharma's General Counsel, Nancy Denyes, Buys $5,000 in Company Stock

Nancy Denyes, General Counsel of aTyr Pharma, recently purchased 5,000 shares of the company's common stock at an average price of $1.8552 per share.

Summary

• On June 5, 2024, Nancy Denyes, the General Counsel of aTyr Pharma, purchased 5,000 shares of aTyr Pharma's common stock.
• The purchase was made at a weighted average price of $1.8552 per share, with individual prices ranging from $1.835 to $1.87 per share.
• Following the transaction, Ms. Denyes directly owns 22,267 shares of aTyr Pharma, which includes 2,500 shares acquired on May 15, 2024, under the company's 2015 Employee Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally viewed favorably, but the amount is relatively small and may not be highly significant.

Positives

• The purchase of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. This purchase by the General Counsel could be interpreted as a positive sign.

Stakeholder Impact

• The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates